Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $27.50.

A number of research firms have recently issued reports on KMTS. The Goldman Sachs Group dropped their price target on Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 16th. Wells Fargo & Company began coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They set an "overweight" rating and a $28.00 target price on the stock. Wolfe Research started coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They issued an "outperform" rating and a $29.00 price target for the company. Bank of America started coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They set a "buy" rating and a $30.00 price objective on the stock. Finally, Stifel Nicolaus initiated coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set a "buy" rating and a $28.00 target price for the company.

Kestra Medical Technologies Trading Up 2.7 %

KMTS stock opened at $24.99 on Friday. Kestra Medical Technologies has a 12 month low of $20.00 and a 12 month high of $26.15.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last posted its quarterly earnings results on Monday, April 14th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same quarter in the previous year, the company earned ($1.18) EPS.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.